NSCLC

ADC Resistance Overcome: ORR Exceeds 41%! The Potential of HER2 TKI Treatment in HER2+ NSCLC

by
ADC Resistance Overcome: ORR Exceeds 41%! The Potential of HER2 TKI Treatment in HER2+ NSCLC

Introduction Zongertinib (BI1810631) is a selective HER2 (ERBB2) tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which covalently binds to the receptor tyrosine kinase domain (TKD) of HER2 exon 20 mutations. This selectivity allows it to block only the abnormal downstream signaling of HER2 without affecting the wild-type epidermal growth factor receptor (wtEGFR, i.e., normal … Read more

Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

by
Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

Source: Professor Zhang Bo The activation mechanisms of the HER-2 gene include amplification, mutation, insertion, and protein overexpression. Although HER-2 is considered a driver gene in lung cancer, no targeted therapeutic drugs have been approved. Recently, Lancet Oncology published efficacy and safety data for the ADC drug DS-8201 targeting HER2 in patients with advanced NSCLC … Read more

2023 ESMO: B7-H3 Targeted ADCs Show Exceptional Efficacy in SCLC and sqNSCLC

by
2023 ESMO: B7-H3 Targeted ADCs Show Exceptional Efficacy in SCLC and sqNSCLC

Updates on the first human study data from Phase I/II show that B7-H3 targeted ADCs continue to demonstrate therapeutic potential. In recent years, antibody-drug conjugates (ADCs) have emerged as a new class of drugs that bring new “hope” to the treatment of advanced cancer patients due to their unique mechanisms of action. The B7 family … Read more